Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early
event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with …

Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung
cancer. Elevated tumor prostaglandin E2 (PGE2), a major COX-2 metabolite, levels have …

Recent advances in the understanding of the biology and molecular biology of lung cancer
has provided targets for novel therapeutic and chemoprevention strategies. The eicosanoid …

Purpose Increased expression of eicosanoids in cancer has been associated with adverse
prognosis. We performed a randomized phase II trial to test the hypothesis that inhibitors of …

Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung
cancer. In non-small cell lung cancer (NSCLC), COX-2 is overexpressed in most …

Lung cancer (LC) is the leading cause of cancer‐related death worldwide, with non‐small
cell lung cancer (NSCLC) comprising 85% of all cases. COX‐2, an enzyme induced …

Preclinical studies suggest that cyclooxygenase (COX)-2 may be involved in the molecular
pathogenesis of some types of lung cancer. Most of the available studies point to its …

Given that lung cancer remains the leading cause of cancerrelated death in the United
States, 1 one might question the value of the last three decades of basic and clinical …

COX is the key enzyme in the conversion of arachidonic acid to prostanoids, potent bioactive
lipid derivatives that participate in normal growth responses and in aberrant cellular growth …

Cyclooxygenase-2 (COX-2) is a key enzyme in the production of prostaglandins and
thromboxanes from free arachidonic acid. Increasing evidence suggests that COX-2 plays a …